Morgan Stanley Arca Biopharma, Inc. Transaction History
Morgan Stanley
- $1.23 Trillion
- Q1 2024
Shares
4 transactions
Others Institutions Holding ABIO
# of Institutions
25Shares Held
7.23MCall Options Held
54.7KPut Options Held
0-
Cable Car Capital LLC San Francisco, CA4MShares$14.4 Million9.73% of portfolio
-
Western Standard LLC Los Angeles, CA1.41MShares$5.09 Million1.2% of portfolio
-
Bml Capital Management, LLC Zionsville, IN707KShares$2.55 Million0.83% of portfolio
-
Vanguard Group Inc Valley Forge, PA454KShares$1.64 Million0.0% of portfolio
-
Black Rock Inc. New York, NY231KShares$834,7690.0% of portfolio
About ARCA biopharma, Inc.
- Ticker ABIO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 14,410,100
- Market Cap $52M
- Description
- ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydr...